Literature DB >> 7122690

Evidence of nonlinear pharmacokinetics of methotrexate in the rat.

E Scheufler.   

Abstract

Three doses (0.31, 3.1 and 31 mg/kg) of methotrexate (MTX) were given intravenously to rats. The resulting concentration-time curves in plasma (normalized by dividing the plasma concentration by a multiple of the dose) were not superimposable, indicating nonlinear plasma pharmacokinetics. In liver, kidney, bone marrow and stomach a tissue-specific, very slowly (or not measurably) decreasing terminal plateau phase could be observed after administration of all three doses. This was explained by a strong binding of MTX to dihydrofolate reductase. The ratio, exchangeable MTX in tissue/plasma concentration, increased in liver and kidney with time after the higher doses, which is in accord with saturable transport to tissues.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7122690     DOI: 10.1159/000137723

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  4 in total

1.  Pharmacokinetics of methotrexate in the extracellular fluid of brain C6-glioma after intravenous infusion in rats.

Authors:  S Dukic; T Heurtaux; M L Kaltenbach; G Hoizey; A Lallemand; B Gourdier; R Vistelle
Journal:  Pharm Res       Date:  1999-08       Impact factor: 4.200

2.  Consideration of Fractional Distribution Parameter fd in the Chen and Gross Method for Tissue-to-Plasma Partition Coefficients: Comparison of Several Methods.

Authors:  Yoo-Seong Jeong; William J Jusko
Journal:  Pharm Res       Date:  2022-03-14       Impact factor: 4.580

3.  Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate in rabbits.

Authors:  H Iven; H Brasch; J Engster
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

4.  Pharmacokinetics of methotrexate (MTX) and 7-hydroxymethotrexate (7-OH-MTX) in rats and evidence for the metabolism of MTX to 7-OH-MTX.

Authors:  L Fahrig; H Brasch; H Iven
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.